Phase 4 N=16 Randomized Quadruple-blind Treatment

Renal and Hormonal Effects of Pioglitazone

Diabetes · Hypertension

Bottom Line

View on ClinicalTrials.gov: NCT01090752 ↗

Enrolled (actual)

Serious AEs

—

Results posted

Apr 2010

Primary outcome: Primary: Effects of Pioglitazone on Renal Hemodynamics — 68.0; 62.4 ml/min/1.73m2

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: Pioglitazone (Drug); Metformin (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: University Hospital, Geneva
Primary completion: Oct 2007

Outcome Measures

Outcome	Result	p-value
PRIMARY Effects of Pioglitazone on Renal Hemodynamics	68.0; 62.4	—
PRIMARY Effects of Pioglitazone on Sodium and Lithium Clearances	1.05; 1.18	—
PRIMARY Effects of Pioglitazone on 24h Blood Pressure Control	128; 129	—
SECONDARY Effects of Pioglitazone on Salt Sensitivity	—	—

Summary

This study examines the effects of pioglitazone on renal sodium handling in subjects prone to insulin resistance, i.e. diabetic and/or hypertensive subjects.

Eligibility Criteria

Inclusion Criteria

Type II Diabetes
Hypertension

Exclusion Criteria

Cardiac or renal diseases
Anaemia
Drugs like aspirin, non steroidal anti-inflammatory drugs and hormonal replacement therapy.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01090752). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.